(Q33959260)

English

The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

30 July 2017

The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy (English)

1 reference

Europe PubMed Central

30 July 2017

0 references

anti-retroviral agent

0 references

Debbie Kamwendo

5

object named as

Debbie Kamwendo

1 reference

Europe PubMed Central

30 July 2017

object named as

Ralf Weigel

3

0 references

9

object named as

Joseph J Eron

1 reference

Europe PubMed Central

30 July 2017

Mina C Hosseinipour

1

object named as

Mina C Hosseinipour

1 reference

Europe PubMed Central

30 July 2017

7

object named as

Susan A Fiscus

1 reference

Europe PubMed Central

30 July 2017

4

object named as

Sam Phiri

1 reference

Europe PubMed Central

30 July 2017

author name string

Joep J G van Oosterhout

2

1 reference

Europe PubMed Central

30 July 2017

Neil Parkin

6

1 reference

Europe PubMed Central

30 July 2017

Julie A E Nelson

8

1 reference

Europe PubMed Central

30 July 2017

Johnstone Kumwenda

10

1 reference

Europe PubMed Central

30 July 2017

language of work or name

0 references

publication date

1 June 2009

1 reference

Europe PubMed Central

30 July 2017

1 reference

Europe PubMed Central

30 July 2017

23

1 reference

Europe PubMed Central

30 July 2017

9

1 reference

Europe PubMed Central

30 July 2017

1127-1134

1 reference

Europe PubMed Central

30 July 2017

Template usage is responsible for the preferential acquisition of the K65R reverse transcriptase mutation in subtype C variants of human immunodeficiency virus type 1.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2896488

5 July 2018

Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2896488

5 July 2018

HIV drug resistance after the use of generic fixed-dose combination stavudine/lamivudine/nevirapine as standard first-line regimen

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2896488

5 July 2018

Predictors of long-term viral failure among ugandan children and adults treated with antiretroviral therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2896488

5 July 2018

Virological response to a triple nucleoside/nucleotide analogue regimen over 48 weeks in HIV-1-infected adults in Africa

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2896488

5 July 2018

The K65R mutation in human immunodeficiency virus type 1 reverse transcriptase exhibits bidirectional phenotypic antagonism with thymidine analog mutations

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2896488

5 July 2018

Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2896488

5 July 2018

A novel genetic pathway of human immunodeficiency virus type 1 resistance to stavudine mediated by the K65R mutation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2896488

5 July 2018

Amino acid substitutions at position 190 of human immunodeficiency virus type 1 reverse transcriptase increase susceptibility to delavirdine and impair virus replication

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2896488

5 July 2018

Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2896488

5 July 2018

A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2896488

5 July 2018

Evaluation of a systematic substitution of zidovudine for stavudine-based HAART in a program setting in rural Cambodia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2896488

29 October 2018

Outcomes from monitoring of patients on antiretroviral therapy in resource-limited settings with viral load, CD4 cell count, or clinical observation alone: a computer simulation model

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2896488

29 October 2018

Prevalence and risk factors for developing K65R mutations among HIV-1 infected patients who fail an initial regimen of fixed-dose combination of stavudine, lamivudine, and nevirapine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2896488

29 October 2018

High frequency of drug resistance mutations in human immunodeficiency virus type 1-infected Korean patients treated with HAART.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2896488

29 October 2018

Molecular mechanisms of bidirectional antagonism between K65R and thymidine analog mutations in HIV-1 reverse transcriptase.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2896488

29 October 2018

HIV-1 subtype C viruses rapidly develop K65R resistance to tenofovir in cell culture.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2896488

29 October 2018

Scaling up antiretroviral treatment in resource-poor settings

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2896488

29 October 2018

Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2896488

29 October 2018

Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2896488

29 October 2018

Lopinavir/ritonavir as single-drug therapy for maintenance of HIV-1 viral suppression: 48-week results of a randomized, controlled, open-label, proof-of-concept pilot clinical trial (OK Study).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2896488

29 October 2018

Antagonism between the HIV-1 reverse-transcriptase mutation K65R and thymidine-analogue mutations at the genomic level

1 reference

https://pubmed.ncbi.nlm.nih.gov/19417582

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Resistance development over 144 weeks in treatment-naive patients receiving tenofovir disoproxil fumarate or stavudine with lamivudine and efavirenz in Study 903

1 reference

https://pubmed.ncbi.nlm.nih.gov/19417582

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails

1 reference

https://pubmed.ncbi.nlm.nih.gov/19417582

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Update of the drug resistance mutations in HIV-1: Spring 2008

1 reference

https://pubmed.ncbi.nlm.nih.gov/19417582

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1097/QAD.0B013E32832AC34E

1 reference

Europe PubMed Central

30 July 2017

1 reference

Europe PubMed Central

30 July 2017

1 reference

Europe PubMed Central

30 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33959260&oldid=1868528816"